NCT04205851View on ClinicalTrials.gov

Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

April 7, 2020

Study Completion Date

April 7, 2020

Conditions
InflammationRheumatic Diseases
Interventions
DRUG

KIN-1901

KIN-1901 is a fully human monoclonal antibody (mAb).

DRUG

Placebo

Saline

Trial Locations (1)

H3P 3P1

Altasciences Clinical Research, Montreal

Sponsors
All Listed Sponsors
lead

Kinevant Sciences GmbH

INDUSTRY

NCT04205851 - Phase 1 Study With KIN-1901 in Healthy Subjects and Subjects With Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter